Tenax Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview

Tenax Therapeutics

16/08/2021 06:50

* Tenax Therapeutics Inc  TENX.OQ   TENX.O  is expected to show
a no change in quarterly revenue when it reports results on
August 16 (estimated). 
​* Refinitiv's mean analyst estimate for Tenax Therapeutics Inc
is for a loss of 13 cents per share. For the same quarter last
year, the company reported a loss of 23 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Tenax
Therapeutics Inc is $4.75​, about 66.9% above​ its last closing
price of $1.57. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.21       -0.21      -1.64     Missed  -681
 Dec. 31 2020  -0.18       -0.14      -0.60     Missed  -328.6
 Sep. 30 2020  -0.13       -0.14      -0.18     Missed  -24.1​
 Jun. 30 2020  -0.21       -0.21      -0.23     Missed  -9.5
 Mar.          -0.19​      -0.19      -0.38     Missed  -100​
 31​ 2020​                                              
 Dec. 31 2019              -0.60      -0.41     Beat    32.2​
 Sep. 30 2019  -0.31       -0.37      -0.33     Beat    12
 Jun. 30 2019  -0.45       -0.40      -0.28     Beat    30.9
 This summary was machine generated August 16 at 05:50 GMT.  All
figures in US dollars unless otherwise stated